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Protocol
AbstrACt 
Introduction  The beneficial effect of dietary omega-3 
supplementation in younger adults or older people with 
acute or chronic disease is established. Knowledge is now 
needed about the effect in medically stable older people. 
The objective of this study is to examine and assess the 
evidence for a role of dietary omega-3 polyunsaturated 
fatty acid (PUFA) supplementation in older adults on (1) 
muscle mass and muscle strength, (2) inflammatory 
biomarkers and (3) physical activity.
Methods and analysis A systematic review and 
data synthesis will be conducted of randomised 
controlled trials in older people not recruited for any 
given disease diagnosis. Placebo-controlled studies 
reporting interventions involving dietary supplementation 
of omega-3 PUFAs, eicosapentaenoic acid and 
docosahexaenoic acid will be included. Outcomes must 
include changes from baseline to last available follow-
up for one or more of the following: muscle mass, 
inflammatory biomarkers, physical activity, walking 
speed, weight change, hand grip strength or muscle 
strength. Once the search strategy has been carried out, 
two independent researchers will assess relevant papers 
for eligibility. Articles up until 31 December 2017 in any 
language will be included. We will provide a narrative 
synthesis of the findings from the included studies. 
Studies will be grouped for meta-analysis according 
to the outcome(s) provided. Where studies have used 
the same type of intervention, with the same outcome 
measure, we will pool the results using a random effects 
meta-analysis, with standardised mean differences for 
continuous outcomes and risk ratios for binary outcomes, 
and calculate 95% CI and two-sided p values for each 
outcome. 
Ethics and dissemination  No research ethics approval 
is required for this systematic review as no confidential 
patient data will be used. The results of this systematic 
review will be disseminated through publication in 
an open-access peer-reviewed journal and through 
conference presentations.
PrOsPErO registration number CRD42017080240.
IntrOduCtIOn
According to the United Nations, the number 
of people aged over 60 years will double glob-
ally from 962 million in 2017 to 2.1 billion 
in 2050.1 In Europe, the proportion of the 
population aged over 60 years is projected to 
reach 35% by 2050.1 It is, therefore, a global 
priority to ensure that this ageing population 
remains independent. A key element of main-
taining independence in older adults is the 
preservation of mobility along with muscle 
mass and strength.
Muscle mass decline is one of the hallmarks 
of ageing and, from age 40 years, muscle 
mass begins to decrease, with an annual 
decline in functional capacity of up to 3% 
per year after age 60 years.2 A key geronto-
logical concept linked to musculoskeletal 
ageing is frailty.3 The commonly acknowl-
edged characteristics include unintentional 
weight loss, self-reported exhaustion, weak-
ness (grip strength), slow walking speed and 
low physical activity.4 This complex phenom-
enon is highly correlated with loss of mobility 
along with progressive loss of skeletal muscle 
strength (dynapenia), mass and function 
(sarcopenia)5 and results in a reduced quality 
of life and is a major public health concern.6
The prevalence of frailty also increases with 
age, and along with sarcopenia is associated 
strengths and limitations of this study
 ► This will be the first study to systematically examine 
the effect of dietary omega-3 fatty acid supplemen-
tation on frailty-related phenotypes in  older adults 
not selected for specific chronic or acute conditions.
 ► An important strength of the study is the focus on 
both functional (walking speed, grip strength, get up 
and go) and inflammatory outcomes (cytokine level) 
outcomes that will allow to put in context the effect 
size and direction of effect of omega-3 supplemen-
tation and to prioritise outcomes for future RCTs.
 ► Results will also help to inform future guidelines on 
dietary supplementation for older adults.
 ► Limitations may include issues of poor reporting af-
fecting risk of bias assessment and confidence in 
results.
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with serious adverse outcomes, including falls, hospital-
isation and mortality.7 There is consensus of an inflam-
matory contribution to frailty. Striking differences in the 
levels of proinflammatory cytokines between frail and 
non-frail elderly have been reported8 and predict higher 
mortality.9
A role for nutritional determinants of frailty has been 
proposed,10 and a number of lifestyle interventions have 
been investigated with regards to frailty, including exer-
cise and increased protein intake.11
Recent work has also begun to investigate such inter-
ventions to prevent or diminish muscle loss in medical 
settings, including the supplementation of leucine,12 
vitamin D13 and fish-derived omega-3 polyunsaturated 
fatty acids (PUFA), eicosapentaenoic acid (EPA) and doco-
sahexaenoic acid (DHA). Studies carried out in a variety 
of populations including cancer patients,14 patients with 
end-stage renal disease,15 chronic obstructive pulmonary 
disease16 and rheumatoid arthritis17 have shown that 
dietary PUFAs have a beneficial effect on skeletal muscle 
mass and strength.
Dietary supplementation of omega-3 PUFAs is of partic-
ular interest in the context of frailty, given its well-known 
anti-inflammatory role and the importance of inflamma-
tion in the development of ageing.18
Omega-3 reduces inflammation in conditions including 
Duchenne muscular dystrophy,19 Crohn’s disease,20 non-al-
coholic fatty liver disease,21 cardiovascular disease22 as well 
as many cancers.14 23–25 These studies are of particular 
interest, as increased levels of inflammatory biomarkers 
such as interleukin-6 (IL-6), tumour necrosis factor-alpha 
(TNF-α) and C reactive protein (CRP) have all been linked 
with both frailty and sarcopenia in older adults.26–28 Long-
chain PUFAs have been suggested to interact with antiox-
idants and improve inflammatory responses to positively 
impact on physical performance.29 Part of the mechanism 
may involve the effect of omega-3 on musculoskeletal 
pain; a pain reduction would be conducive to more phys-
ical activity.30 More generally, omega-3 supplementation 
may act directly on skeletal muscle and improve protein 
metabolism hence having an influence on physical perfor-
mance.31 32 A more proinflammatory diet has also been 
linked with a higher incidence of frailty.33
A recent review by Ticinesi et al18 summarised the anal-
ysis of omega-3 PUFAs on inflammation in older individ-
uals in both cross-sectional and randomised controlled 
trials (RCTs). However, we are not aware of any system-
atic reviews or meta-analyses focusing specifically on 
omega-3 fatty acid supplementation on frailty phenotypes 
in older adults not selected for any specific chronic or 
acute conditions. We propose to conduct a systematic 
review and meta-analysis to examine the effect of dietary 
omega-3 supplementation in older people not recruited 
for any given disease diagnosis. The outcomes that will be 
investigated are inflammatory biomarkers, muscle mass, 
physical activity, walking speed, weight change, hand 
grip strength or muscle strength, as well as biases in the 
included studies.
MEthOds And AnAlysIs
registration
This protocol has been registered with PROSPERO 
(registration number CRD42017080240)34 and reported 
in accordance with Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA)35 and PRIS-
MA-Protocol36 37 guidelines.
study selection criteria
Interventions and population
Studies reporting results of interventions involving 
dietary supplementation of omega-3 PUFAs will be 
included. Dietary supplementation will be defined as 
daily ingestion of capsules containing EPA and DHA or 
through an EPA and DHA-enriched diet. The compar-
ator will be placebo-controlled groups. Participants will 
include community-dwelling persons, of either sex, clas-
sified by the study authors as postmenopausal or older 
people with the majority of participants over 60 years of 
age. To ensure the focus of the review is on older people 
not recruited for any given disease diagnosis, exclusions 
will be studies where participants were selected because 
they had a cancer or other chronic disease diagnosis. 
Participants who currently consumed a high fish diet or 
use fish oil supplements will also be excluded.
Outcomes
Outcomes must include changes from baseline to last avail-
able follow-up for one or more of the following: muscle 
mass, inflammatory biomarkers, physical activity, walking 
speed, weight change, hand grip strength or muscle 
strength. Any adverse effects will also be summarised. 
Studies will be grouped for meta-analysis according to the 
outcome(s) provided.
Study designs
RCTs will be included.
Other
Articles up until 31 December 2017 in any language will 
be included.
Exclusion criteria
Studies will be excluded for the following reasons: (1) 
study population was specifically focused on partici-
pants diagnosed and being treated for a pre-existing 
medical condition (eg, cancer, kidney disease, liver 
disease, diabetes mellitus and cardiovascular disease); or 
(2) letters to the editor, meta-analyses, case reports and 
reviews.
Search strategy
MEDLINE (Ovid) from 1946, the Cochrane Register of 
Controlled Trials (CENTRAL) from 1940, Embase from 
1946, Cumulative Index to Nursing and Allied Health 
Literature from 1937, Allied and Complementary Medi-
cine Database and Web of Science will be searched for 
relevant trials. The search strategy for Medline has been 
developed in consultation with a subject-specific librarian 
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and will be adapted for use in other databases. Search 
terms are informed by Cochrane Handbook38 and other 
systematic reviews investigating PUFA dietary supplemen-
tation, sarcopenia and/or frailty.
The full search strategy can be found in the online supple-
mentary file 1. Example of searches that will be used can 
be seen in online supplementary file 2, box 1 MEDLINE 
(OVID) Advanced Search Example. Syntax (truncation, 
wildcards and quotation marks) and operators will be 
amended according to the specific databases. Initial search 
results will be uploaded to EndNote X7 (Thomas Reuters) 
prior to the review of titles and abstracts.
Data extraction
Initial title and abstract review will be conducted by 
the first author (JS). Duplicates and articles clearly not 
meeting the selection criteria will be removed. The 
reference lists from identified letters to the editor, 
meta-analyses, case reports and reviews will be scanned 
to identify further trials. Two independent researchers 
(JS and AMV) will then read the full text of remaining 
relevant papers for eligibility. In cases where the two 
researchers cannot agree on eligibility, a third researcher 
will mediate. Authors of grey literature will be contacted 
when conference abstracts and proceedings are found. A 
PRISMA flow chart will be used to provide transparency 
of the number of papers included or excluded at each 
stage. Two independent researchers (JS and AMV) will 
extract the data. The data extracted from the studies (if 
available) will include (1) authors; (2) publication year; 
(3) country; (4) funding; (5) setting; (6) study design; 
(7) sample size; (8) dosage; (9) duration of monitoring 
or intervention; (10) withdrawals; (11) mean age; (12) 
gender; (13) muscle mass; (14) physical activity; (15) 
muscle strength; (16) walking speed; (17) weight; (18) 
hand grip strength; and (19) biomarkers.
Risk of bias assessment
Reporting bias will be assessed by plotting the inverse of 
the SEs of the effect estimates using funnel plots where 
meta-analysis includes more than 10 trials and will be 
assessed visually for asymmetry39 and with the Egger’s 
regression test for continuous variables.40 Analysis will be 
conducted on Review Manager Software.41
JS and AMV will independently assess the risk of study 
bias using the Cochrane Collaboration’s tool for assessing 
risk of bias in randomised trials.42 The Cochrane risk of 
bias tool for RCTs consists of the following seven items: 
(1) random sequence generation; (2) allocation conceal-
ment; (3) blinding of participants and personnel; (4) 
blinding of outcome assessment; (5) incomplete outcome 
data; (6) selective reporting; (7) other sources of bias. 
Questions are rated as having a high, low or unclear level 
of bias across the seven domains.
Strength of evidence evaluation
Strength of evidence will be assessed by Grades of Recom-
mendation Assessment, Development and Evaluation 
(GRADE) system,43 that is, quality of evidence for each 
outcome, relative importance of outcomes and overall 
quality of evidence.
Data management and statistical analysis
Data obtained through data extraction will be entered 
into Excel. Outcomes will be imported into RevMan41 
for meta-analysis. Data extracted must be presented as 
mean and SD, not ranges, and will not be estimated from 
graphs or figures. Authors will be contacted if mean and 
SD values are not presented.
We will create a table describing study characteristics 
and major outcomes. We will provide a narrative synthesis 
of the findings from the included studies, structured 
around the type and content of intervention (ie, diet alone 
or in combination with training), target population char-
acteristics (ie, sex, age and body mass index (BMI)), type 
of outcome (ie, muscle strength, physical performance, 
muscle mass and cognitive function). We will provide 
summaries of intervention effects for each study by calcu-
lating risk ratios (for dichotomous outcomes) or stan-
dardised mean differences (for continuous outcomes).
We anticipate that there will be limited scope for 
meta-analysis because of the range of different outcomes 
measured across the small number of existing trials. 
However, where studies have used the same type of inter-
vention, with the same outcome measure, we will pool the 
results using a random effects meta-analysis, with stan-
dardised mean differences for continuous outcomes and 
risk ratios for binary outcomes, and calculate 95% CI and 
two-sided p values for each outcome. In studies where the 
effects of clustering have not been taken into account, 
we will adjust the SD for the design effect. Heterogeneity 
between the studies in effect measures will be assessed 
using the I² statistic.44 We will consider an I² value greater 
than 50% indicative of moderate heterogeneity or 75% 
high heterogeneity.45
We will conduct sensitivity analyses based on study 
quality. We will use stratified meta-analyses to explore 
heterogeneity in effect estimates according to partici-
pant characteristics (eg, sex, age and BMI), location (eg, 
hospital or community setting), intervention components 
(eg, diet alone or in combination with training) and the 
logistics of intervention provision.
Outcomes and prioritisation
The primary outcomes will include recognised frailty 
criteria of physical activity levels, walking speed, 
hand grip strength or muscle strength and weight4 along 
with changes in muscle mass and circulating levels of the 
proinflammatory markers CRP, IL-6 and TNF-α.
Other outcomes will be analysed if available including 
body fat mass.
Patient and public involvement
The research question was developed following a patient 
involvement event in May 2017 with members from 
Arthritis Research UK Pain Centre and National Institute 
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for Health Research Biomedical Research Centre Muscu-
loskeletal PPI group. Members of the PPI group informed 
the authors that they already take a number of phar-
maceutical treatments and they have a preference for 
learning more about possible lifestyle interventions, 
such as dietary modification where they can take control 
of their only health and well-being. Patients were not 
involved in the design of this systematic review.
EthICs And dIssEMInAtIOn
No research ethics approval is required for this system-
atic review, as no confidential patient data will be used. 
It is intended that the results of this systematic review will 
be disseminated through publication in an open-access 
peer-reviewed journal and through conference presen-
tations. All amendments to the protocol will be docu-
mented, dated and reported in the PROSPERO trial 
registry.
dIsCussIOn
This systematic review will use rigorous methodology 
to identify and examine studies reporting the outcome 
of omega-3 supplementation on frailty-related traits on 
ageing groups not selected for specific chronic or acute 
conditions, including both inflammatory biomarkers and 
functional measures. No systematic review has previously 
addressed this objective, although numerous published 
reviews have focused on ageing populations suffering 
from chronic or acute conditions. For example, there is 
evidence of beneficial effects of omega-3 supplementa-
tion for individuals undergoing chemotherapy or radio-
therapy for cancer46 for risk reduction in individuals with 
established atherosclerotic cardiovascular disease47 and 
some beneficial effect on liver function in individuals 
with non-alcoholic fatty liver disease48 among others.
Although risk of bias and overall level of evidence may 
limit analyses and confidence in this review’s conclusions, 
this synthesis will provide a better understanding of the 
effect of omega-3 supplementation in preventing systemic 
inflammation and functional decline in the elderly 
population.
Implications of results
This review will provide the first rigorous summary of 
effect of omega-3 supplementation across all published 
randomised controlled trial studies of elderly individuals 
not selected for chronic or acute conditions. The find-
ings will inform our understanding of the value of this 
popular nutritional supplement in preventing frailty-re-
lated outcomes.
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